# Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

> **NCT00517361** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 11 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00517361
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2011-04
- **Final completion:** 2012-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** This study has been terminated due to poor accrual
- **Last updated:** 2014-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517361, "Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-20 from https://api.ai-analytics.org/clinical/NCT00517361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*